Navigation Links
Organovo To Present At Lazard Healthcare Conference

SAN DIEGO, Nov. 7, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo"), a developer and manufacturer of functional human tissues using a novel three-dimensional  bioprinting technology, today announced that Keith Murphy, Chairman and Chief Executive Officer, will present at the upcoming Lazard Capital Markets 9th Annual Healthcare Conference in New York.  Mr. Murphy is expected to present on Wednesday, November 14, 2012. 

About Organovo Holdings, Inc.

Organovo designs and creates functional human tissues using a proprietary three dimensional bioprinting technology. The Company focuses on developing a range of human tissues and disease models for medical research and therapeutic applications.  The Company's NovoGen three-dimensional bioprinting technology uses a specialized automated platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's technology can also be applied to create surgical tissues for direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current report on Form 8-K/A filed on May 11, 2012. We do not undertake to update these forward-looking statements made by us.

SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Organovo, Inc. to Webcast, Live, at on March 1st
3. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at
4. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
5. Organovo Announces Relocation and Commencement of Operations at Larger Facility
6. Organovo Holdings, Inc. to Webcast, Live, at on August 2nd
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... , November 25, 2015 ... Research Report is a professional and in-depth study ...      (Logo: ) , ... of the industry including definitions, classifications, applications and ... provided for the international markets including development trends, ...
(Date:11/24/2015)... SUNNYVALE, Calif. , Nov. 24, 2015 ... executives will be speaking at the following conference, and ... New York, NY      Tuesday, December 1, ... New York, NY      Tuesday, December 1, ...      Piper Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for Pharmaceutical Engineering ... premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place ... the largest number of attendees in more than a decade. , “The ...
Breaking Biology Technology:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Capacitive Fingerprint Sensors - Technology and Patent Infringement Risk ... --> --> Fingerprint sensors using ... smartphones. The fingerprint sensor vendor Idex forecasts an increase ... in mobile devices and of the fingerprint sensor market ...
(Date:11/20/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet, ... interviewed on The RedChip Money Report television ... Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, and ... ) ("NXT-ID" or the "Company"), a biometric authentication company ...
(Date:11/19/2015)... MOUNTAIN VIEW, Calif. , Nov. 19, 2015 /PRNewswire/ ... authentication market, Frost & Sullivan recognizes BIO-key with the ... Strategy Leadership. Each year, Frost & Sullivan presents this ... comprehensive product line catering to the needs of the ... which the product line meets and expands on customer ...
Breaking Biology News(10 mins):